Who are AQX-1125's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): BMS-986205, Both deferoxamine mesylate and colchicine, BMS-986278, Al(OH)3.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/aqx-1125.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

AQX-1125 — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

AQX-1125 (AQX-1125) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NLRP3 inflammasome inhibitor. Area: Rheumatology.

phase 2 NLRP3 inflammasome inhibitor NLRP3 Rheumatology Small molecule Live · refreshed every 30 min

Target snapshot

AQX-1125 (AQX-1125) — Aquinox Pharmaceuticals (Canada) Inc.. AQX-1125 is a small molecule that inhibits the NLRP3 inflammasome.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
AQX-1125 TARGET	AQX-1125	Aquinox Pharmaceuticals (Canada) Inc.	phase 2	NLRP3 inflammasome inhibitor	NLRP3
BMS-986205	BMS-986205	Bristol-Myers Squibb	phase 3	NLRP3 inflammasome inhibitor	NLRP3
Both deferoxamine mesylate and colchicine	Both deferoxamine mesylate and colchicine	The George Institute	phase 3	Iron chelator + anti-inflammatory combination	Labile iron (deferoxamine); microtubule polymerization and NLRP3 inflammasome (colchicine)
BMS-986278	BMS-986278	Bristol-Myers Squibb	phase 3	NLRP3 inflammasome inhibitor	NLRP3
Al(OH)3	Al(OH)3	Janssen Vaccines & Prevention B.V.	phase 3	Vaccine adjuvant	NLRP3 inflammasome; antigen-presenting cells

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NLRP3 inflammasome inhibitor class)

Bristol-Myers Squibb · 2 drugs in this class
Aquinox Pharmaceuticals (Canada) Inc. · 1 drug in this class
Astellas Pharma Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AQX-1125 — Competitive Intelligence Brief. https://druglandscape.com/ci/aqx-1125. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing